KIT and gastrointestinal stromal tumor: The incomplete coverage of imatinib-resistant KIT mutations by each of these drugs allows cross-resistant GIST subclones to emerge from a background of heterogeneous GIST cells with varied KIT secondary mutations, leading to clinical progression irrespective of the TKI used.